Navigation Links
Researchers identify a molecule that increases the risk of cardiac insufficiency
Date:4/24/2009

This release is available in Spanish.

A team of scientists from the Center for Applied Medical Research (CIMA) of the University of Navarra has identified a key enzyme in the development of cardiac insufficiency. This enzyme is involved in the accumulation of fibrous tissues in the hearts of patients with chronic cardiac diseases and deterioration of heart functions.

The research project, published in the journal Hypertension, is part of a project of the "Red Europea de Excelencia en Hipertensin y Enfermedades Cardiovasculares" [European Network of Excellence in Hypertension and Cardiovascular Diseases], in which research groups from Belgium, the Netherlands, Italy, Great Britain, France, Germany, Finland and Poland are all participating. The project also forms part of the "Red Espaola de Investigacin de las Enfermedades Cardiovasculares" [Spanish Network for Research on Cardiovascular Diseases].

Today, cardiac insufficiency affects more than 1,250,000 Spanish men and women over the age of 45. More than half of these people have a life expectancy of less than five years. The accumulation of fibrosis in the heart has been proven to have a significant influence on the development of cardiac insufficiency among patients with chronic heart disease.

New methods for treating patients with heart disease

The research team from the CIMA analyzed the expression of Llysyl oxidase, an enzyme which regulates the amount of fibrous tissue in cardiac muscle. "By means of molecular and histological methods, we have found that the cardiac muscle in patients with cardiac insufficiency contains an excess of this enzyme as well as collagen fiber (which it produces). These factors are associated with the deterioration of cardiac functions," explained Dr. Begoa Lpez, Lead Researcher of the project.

According to the researchers, this project shows that some drugs prescribed for patients with cardiac insufficiency do not actually inhibit the enzyme lysyl oxidase, nor do they reduce fibrosis or improve heart functions. Other drugs however, which are less commonly used, do have these beneficial qualities. "Our work opens new possibilities for treating patients with heart disease through the inhibition of the enzyme. The development of cardiac insufficiency could thus be impeded," said Begoa Lpez.


'/>"/>

Contact: Oihane Lakar
oihane@elhuyar.com
34-943-363-040
Elhuyar Fundazioa
Source:Eurekalert

Related biology news :

1. Researchers discover that gene switches on during development of epilepsy
2. Researchers report moderately large potential for red tide outbreak in Gulf of Maine region
3. UT Southwestern researchers probe kidney damage, protection in lupus
4. Researchers use brain interface to post to Twitter
5. TGen researchers discover possible way to block the spread of deadly brain tumors
6. Burnham researchers present at 100th AACR Meeting
7. Yale researchers uncover secrets of salmonellas stealth attack
8. Singapore researchers first to transform carbon dioxide into methanol
9. Researchers identify specific lung cancer susceptibility gene
10. CSHL researchers explain process by which cells hide potentially dangerous DNA segments
11. Stem cell therapy makes cloudy corneas clear, according to Pitt researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... -- The latest mobile market research from Acuity Market Intelligence ... quarterly average price of a biometric smartphone decreased from ... There are now 120 sub-$150 models on the market ... 28 a year ago at an average price of ... , Acuity Market Intelligence Principal, "Biometric Smartphones are a ...
(Date:1/19/2017)... PUNE, India , January 19, 2017 According ... Market, Opportunities and Forecast, 2014 - 2022," the global biometric sensor market ... 9.6% from 2016 to 2022. In 2015, Asia-Pacific dominated ... both public and private sectors. Continue Reading ... ...
(Date:1/18/2017)... , Jan. 18, 2017  In vitro diagnostic (IVD) ... mergers and acquisitions (M&A), and Kalorama Information expects that ... acquisitions have been shifting. Generally, uncertainty in reimbursement and ... the U.S. has changed the acquisitions landscape. Instead of ... in companies buying partners outside of their home country ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... 2017 China Cord Blood Corporation (NYSE: ... provider of cord blood collection, laboratory testing, hematopoietic stem ... its unaudited financial results for the third quarter and ... 31, 2016. Third Quarter of Fiscal 2017 ... of fiscal 2017 increased by 18.6% to RMB200.9 million ...
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... , Feb. 23, 2017  In Atlanta, it seems ... fashion, and culture intertwine to create an expressive and dynamic ... reflect this energy and contribute to it. ... Hair Fairies seeks to carry on that tradition ... Atlanta salon is the newest of ...
(Date:2/23/2017)... ... 2017 , ... David Nolte, PhD accepted Purdue University’s 2016 ... Research Park of West Lafayette, Indiana. , The top commercialization award is ... success with, commercializing discoveries from Purdue research. “This award is truly an honor. ...
Breaking Biology Technology: